|
Table 2: Criteria for ambulatory anticoagulation. |
||
|
Group |
Findings |
Management |
|
7 Full anticoagulation |
Present 2 or more of the following • Patients with 2 or more comorbidities • Basal saturation less than 90% • Markers of thrombosis or inflammation with severe increase • Severe injuries in radiology |
Rivaroxaban 30 mg/day (15 mg every 12 hours) for 10 days (+) |
|
6 Formal Anticoagulation more anti-aggregation |
Presence of any of those previous • Comorbidities: 2 or more • Previous management with anticoagulation or anti-aggregation • Markers of thrombosis or inflammation with a moderate increase • Moderate injuries in radiology |
Rivaroxaban 15 to 20 mg/day (+) or apixaban 10 mg/day for 15 days (+) more clopidogrel 75 mg or ASA 100 mg/day |
|
5 Formal |
Presence of 1 or more of those previous • Comorbidities: 1 or more • Markers of thrombosis or inflammation with a moderate increase • Previous anticoagulation and/or anti-aggregation management • Moderate injuries in radiology |
Rivaroxaban 15 to 20 mg/day or apixaban 10 mg/day for 15 days (+) |
|
4 Prophylactic anticoagulation and anti-aggregation |
Presence of 2 or more of those previous • Comorbidities 1 or more • Previous separate management of prophylactic anticoagulation and/or anti-aggregation • Mild injuries in radiology |
Rivaroxaban 5 to 10 mg/day or apixaban 2.5 mg every 12 hours more clopidogrel 75 mg/day or ASA 100 mg/day for 15 days (+) |
|
3 Prophylactic |
Presence of anyone • Comorbidities 2 or more • Minor injuries in radiology |
Rivaroxaban 5 to 10 mg/day or apixaban 2.5 mg every 12 hours for 30 days |
|
2 Anti-aggregation |
Presence of • Comorbidities 1 or more |
Clopidogrel 75 mg/day or ASA 100 mg/day for 30 days |
|
1 Without drug |
• Absence of comorbidities • Laboratories and radiology in normal ranges • Basal saturation greater than 90% |
Without antithrombotic pharmacological management |
|
Criteria for initial referral to other healthcare centers |
• Patients with tachypnea, hemodynamic instability, intolerance to the oral route • Stroke in the past year • Known presence of vascular malformations • History of gastric ulcer, polyps, epistaxis, hypermenorrhea, or history of bleeding or hemorrhage in the last six months • History of seizures or psychiatric illness • Uncontrolled hypertension (SAT > 150 mmHg or TAD > 90 mmHg) • Previous management with vitamin K inhibitors • History of liver or kidney failure |
|
|
Criteria for suspending outpatient oral anticoagulant management |
• Hemorrhage: major bleeding or presence of minor bleeding on 2 or more occasions • Hypertensive crisis: all patients were asked to have a digital manometer at home and to administer each dose of anticoagulant only if the previous pressure measurement was within normal ranges. In the case of high values, management with oral amlodipine 5 mg was indicated. If the pressure was controlled within the 1st hour, the anticoagulant intake was allowed to continue. Otherwise, the continuity of the study will be evaluated • Neurological or alertness disorders • Decision to transfer to the hospital due to clinical deterioration or request of the patient • Lack of attachment to driving • Loss to follow up • Express the patient’s desire to discontinue the anticoagulant |
|